👏Another great meeting of @eortc.org #QualityofLife Group coming to an end. Many projects, collaborations, inspiring discussions &exchanges of ideas💡 Thank you for joining us, see you in Berlin in April 2026! #QLGmeeting #GivingVoice2Patients @mogensgroenvold.bsky.social @dirkhofmeister.bsky.social

💡 Insightful panel discussion as part of @eortc.org #QualityofLife Group autumn meeting closing plenary session. We look forward to broadening our collaborations in global context🤝 #QLGmeeting #GivingVoice2Patients @winettevandergraaf.bsky.social @miekevhr.bsky.social www.eortc.org/event/eortc-...

Excited to host - for the third time - this meeting of a scientific group that I joined in 1989, and which has since made a very substantial contribution to its field.

👏🏼 Welcome to the @eortc.org #QualityofLife Group autumn meeting 2025 in sunny Copenhagen! 🇩🇰 We have a packed room for the welcome session and a busy programme for the two days ahead - looking forward to another productive meeting! 💪🏼 #GivingVoice2Patients #QLGmeeting

🌟Attending the 3rd International Multidisciplinary Anal Cancer Conference (IMACC 2025) in Leeds today &tomorrow? Don't miss the 3 poster presentations & mini oral presentation by our @eortc.org #QualityofLife Group members Samantha Sodergren & Daniel Aze 👇 More info: english.events/imacc2025/co...

📢 Attending #EAPM2025 this week? Today, our @eortc.org #QualityofLife Group member Ines Rathgeber will report on the development of an e-learning course focusing on the use of EORTC PRO measures for quality of life assessment in clinical practice 👇 eapm.eu.com/2025-eapm-co... #CancerResearch

👏 Proud to see this new policy review by Ian Tannock et al. in @thelancetoncol.bsky.social! It highlights the need for standardised HRQoL responder criteria for better patient care & clinical decision-making. 👉 eortc.org/blog/2025/09... #QualityofLife #GivingVoice2Patients @madelinepe.bsky.social

🎯 New date! Join EORTC on 24 Sept 2025 for Treatment Optimisation: Making Cancer Treatment Accessible & Sustainable in Europe, hosted by Mrs Tilly Metz at the @europarl.europa.eu. 🗓️ 24 Sept 📍 EU Parliament & online 🔗 www.eortc.org/event/eortc-... ⚠️ Previous registrations are invalid.

📢 Final reminder to please register by 1st September (extended deadline) if you wish to attend the @eortc.org #QualityofLife Group autumn Meeting 2025: 📅 25-26 September 📍 Copenhagen (DK) 🔗 Registration link in invitation email 🔎 Info on programme etc: www.eortc.org/event/eortc-... #QLGmeeting

🚨Important findings in K Taylor et al. study on life after head & neck cancer: long-term toxicities affect most survivors — highlighting the need for better patient support & tailored follow-up care. doi.org/10.1002/ijc.... #CancerCare #GivingVoice2Patients #QualityofLife @uiccofficial.bsky.social

Are cancer treatments truly optimised for patients? Our CEO, Denis Lacombe, shares why treatment optimisation must be central to cancer care, and how EU policy can help. 🔗 europeancancer.org/resources/ne... #CancerCare #TreatmentOptimisation

🧠 New publication on survivors of oligodendroglioma highlights long-term impacts on health-related #qualityoflife and cognitive functioning. An international cross-sectional study from the @eortc.org Quality of Life Group study team. 🔗 doi.org/10.1093/neuo...  #NeuroOncology #GivingVoice2Patients

📅 Reminder: Registration is open for the @eortc.org #QualityofLife Group (QLG) autumn meeting, to be held on 25-26 September in Copenhagen! ⏰ Register by 19th August to secure your place! 🔗More info including on venue & programme: www.eortc.org/event/eortc-... #QLGmeeting

📢 A unique opportunity to contribute to meaningful, patient-focused research in oncology. If you are looking to deepen your experience in #QualityofLife studies within clinical trials, this @eortc.org Fellowship is an excellent step forward. Join our team!👇 www.eortc.org/job/fellowsh...

📢 Attending the Research & Innovation Conference at @leedsth.nhs.uk today? 🎤 Rose Peacock is presenting a poster on behalf of @eortc.org #QualityofLife Group on the current use of customised Patient-Reported Outcome (PRO) item lists in #CancerResearch. More info: www.leedsth.nhs.uk/research/ri-...

🎤“#EUHTA's regulation offers a framework for collaborative assessment, potentially speeding up patient access to new treatments. But it overlooks treatment optimisation & post-licensing studies. Balanced systems are key to patient-centricity,” Denis Lacombe at EU HTA conference.

📣 Registration is now open for the @eortc.org #QualityofLife Group (QLG) autumn meeting, on 25-26 September in Copenhagen (DK)! ✉️ Registration link sent to all EORTC QLG members by email today 🔎 More information on venue, programme, etc, available here: www.eortc.org/event/eortc-... #QLGmeeting

📢 Team of international researchers establish @eortc.org QLQ-F17 as an equivalent to EORTC QLQ-C30 to assess functioning in cancer patients. 👉 Learn more about this recent study in the related news release just published: qol.eortc.org/researchers-... #QualityofLife @mogensgroenvold.bsky.social

🎤 Excited to share another upcoming presentation today at the 9th UK #PROMs conference! 👉 Christopher Bedding from @eortc.org #QualityofLife (QoL) Group will present new guidelines for the use of patient-reported outcome (PRO) item libraries to allow more flexible PRO assessment in #CancerCare.

👏 Samantha Sodergren from @eortc.org #QualityofLife (QoL) Group presenting today at the 9th UK #PROMs conference! ⏩QLQ-AYA30, 1st QoL tool for Adolescents & Young Adults with cancer ⏩QLQ-ANL27, validated QoL measure for anal cancer post-chemoradiotherapy #CancerResearch @unibirmingham.bsky.social

🌟 Kicking off the first official day of #STATS2025🌟 🔍 Over the next few days our participants will acquire a greater understanding of the statistical principles whilst avoiding too technical formulations #CancerResearch #ClinicalTrials #StatisticalMethods #ClinicalResearch #StatisticsForResearch

👋 Attending #EIE2025 this week? Make sure to stop by poster 303 from @msztankay.bsky.social today to hear more about the finalisation of a guideline for interpreting @eortc.org patient-reported outcome (PRO) measures. More info: implementation.eu/eie2025-prog... #QualityofLife #CancerResearch

🚀 New publication by Florian Zeman et al. shows that future clinical studies can use the @eortc.org QLQ-F17 questionnaire as a generic tool without losing comparability to studies using the QLQ-C30. 🔗 Read more here: doi.org/10.1016/j.ec... #CancerResearch #QualityofLife #GivingVoice2Patients

🆕 The EORTC 2024 Annual Report is out now! We are proud to share a year of progress in independent, patient-centred #CancerResearch, powered by collaboration and innovation. Explore our highlights, new scientific strategy, and vision for the future. 🔗 www.eortc.org/blog/2025/06... #Oncology

📊 Don't miss @eortc.org #STATS2025! Late rate ending today 👇 #CancerResearch #ClinicalResearch

🔁 A must-read from @eortc.org! Eva Gamper et al. make the case for cancer-specific #QualityofLife tools in economic evaluations—crucial in the context of the recent EU HTA reform. 🌍 Read more: www.eortc.org/blog/2025/05... #GivingVoice2Patients @thelancetoncol.bsky.social @madelinepe.bsky.social

On #ClinicalTrialsDay, meet the next generation driving #CancerResearch forward. 👩🏻‍⚕️ In this video, Ioannis, Jens, and Antonella share what it means to be part of the EORTC Early Career Investigator community. Learn more: www.eortc.org/blog/2025/05... ▶️ youtu.be/cjPQDCxrZbI

📢 Join our @eortc.org quality of life team and work with us to make a difference for cancer patients' health-related quality of life 🌻 More info: www.eortc.org/job/fellowsh... And below 👇 #QualityofLife #Oncology #GivingVoice2Patients

👏 A powerful two days focused on what truly matters: the patient voice in #CancerResearch. Let’s keep pushing for trials that reflect what patients value most. 🌻 🔎 Read the 6th @eortc.org #QualityofLife Conference wrap-up here: www.eortc.org/blog/2025/05... #QoLConf25 #GivingVoice2Patients

Thank you for the kind invitation to share insights on the value of PROs in phase I dose-finding trials. A fantastic conference in the beautiful city of Barcelona - I’ve learnt so much too! Such a privilege to be part of it!

🎀 That’s a wrap on the 6th @eortc.org QoL Conference in Barcelona! A huge thank you to all our incredible speakers and chairs, engaged participants, and dedicated organisers for making these two days a true success. 👏 #QoLConf25 #QualityofLife #CancerResearch #GivingVoice2Patients

🔚 SESSION 9 closed the day with insights into electronic & digital outcome assessments in cancer trials and care Thanks to Paul O’Donohoe, Bernhard Holzner & Katarzyna Wac Chaired by @bettinaryll.bsky.social & Lonneke van de Poll-Franse #QoLConf25 #CancerResearch

📱 Digital health technologies are shaping the future of QoL assessment—offering new digital endpoints and improving clinical outcomes. A promising path for patient-centered care. - K. Wac delivering the closing presentation at @eortc.org #QoLConf25 #QualityofLife #GivingVoice2Patients

💪 Bernhard Holzner tackled the real-world challenges of integrating electronic PROs & digital health in clinical care. Key takeaways: sustainability & tested facilitators. @eortc.org #QoLConf25 #GivingVoice2Patients

💻 Implementing PROs and digital health in clinical trials comes with challenges—flexibility, regulatory needs, and reducing missing data are all important aspects to consider. - P. O'Donohoe @eortc.org #QoLConf25 #GivingVoice2Patients #CancerResearch

🔚 SESSION 8 focused on PROs in real-world evidence and patient care Speakers included Michael Brundage, Galina Velikova, August Zabernigg, Lonneke van de Poll-Franse, @bettinaryll.bsky.social & Erik Briers Chairs: Anja Schiel & Jaap Reijneveld #QoLConf25 #CancerResearch

🌍 Erik Briers (Europa Uomo) shared powerful insights on using PROs as real-world data—highlighting the value of evidence-based care through the patient’s eyes. @eortc.org #QoLConf25 #GivingVoice2Patients #CancerResearch

🌸 Insights from PRIME-ROSE show the value—and challenge—of using PROs in real-world precision medicine trials. Multi-stakeholder input is key to making it work in practice. @bettinaryll.bsky.social @eortc.org #QoLConf25 #GivingVoice2Patients

🌟 Lonneke van de Poll-Franse shared valuable insights on incorporating PROs in registries. Her talk covered how real-world data can enhance survivorship care and tackle new challenges in an aging population. @eortc.org #QoLConf25 #GivingVoice2Patients

🌍 PROs in real-world care are valuable—but challenging. Symptoms shift fast, patients tire of forms, and answers aren't always clear. Still, thoughtful design + team support can make HRQoL part of everyday care. - A. Zabernigg at @eortc.org #QoLConf25 #GivingVoice2Patients #CancerResearch

📚 20 years of evidence of symptom monitoring in daily oncology practice. Galina Velikova highlighted how ePROs can improve patient outcomes and streamline clinical workflows. @universityofleeds.bsky.social @eortc.org #QoLConf25 #GivingVoice2Patients

🩺 Michael Brundage from Cancer Care Ontario shared the early adoption of Patient-Reported Outcomes (PROs) in clinical practice. He addressed the journey, lessons learned, and the impact on patient care and research. @ontariohealth.bsky.social @eortc.org #QoLConf25 #GivingVoice2Patients

🔚 SESSION 7 explored statistical considerations for PROs in cancer trials, from RCTs to Phase 1 Thanks to Corneel Coens, Antoine Regnault, Jammbe Musoro & @christinayap.bsky.social Chairs: @madelinepe.bsky.social & Naomi Kiyota #QoLConf25 #CancerResearch

🩺 Phase 1 oncology trials focus on safety—but PROs can add real value. They complement clinician-reported dose-limiting toxicity (DLTs), offering a fuller view of treatment impact. Interest is growing across patients, researchers & regulators. - @christinayap.bsky.social @eortc.org #QoLConf25

📊 Single Arm Trials (SATs) play a growing role in oncology, especially for rare or late-stage cancers. While interpretation can be tricky, they can be ethically and scientifically sound. The estimand framework helps link questions to clear analysis goals. - J. Musoro @eortc.org #QoLConf25

🔍 How to ensure a fair comparison between treatment options? Some guidance: tailor the PRO endpoint to the PRO objective you want to demonstrate & consider tolerability as a crucial concept. Ensure you're on the right track from the onset – it's worth it! - A. Regnault @eortc.org #QoLConf25

📊 PRO data are rich but complex—HRQoL is subjective, and that’s its strength. Clear aims are key. The estimand framework + SISAQOL-IMI guidance help define better objectives and analyses for PROs. - C. Coens at @eortc.org #QoLConf25 #GivingVoice2Patients #CancerResearch

🔚 SESSION 6 highlighted the role of PROs/HRQOL in regulatory & HTA decision-making. Thanks to Anja Schiel, Juan García Burgos, Kirsten Janke, Jan Liliemark & Sigrid Klaar. Chairs: Jan Geissler & Sigrid Klaar #QoLConf25 #CancerResearch #GivingVoice2Patients @eortc.org

⚖️ Including Patient-Reported Outcomes (PROs) in trials means balancing effort vs. value—for patients, trial teams, and industry. The big question: will PROs impact product success? Clear, well-collected data are key. - S. Klaar @eortc.org #QoLConf25 #GivingVoice2Patients #CancerResearch